

It is the responsibility of every individual to check that this is the latest version/copy of this document.

Key amendments to this guideline

Date	Amendment	By:
11/07/11	Title: Management of Hyperosmolar Non-Ketotic State (HONK)/ Hyperglycaemic Hyperosmolar State (HHS).	D. Jenkins
11/07/11	Change of mortality figure from 50% to 10%	D. Jenkins
November 2016	Documents extended for 12 months as per TMC paper approved on 22 nd July 2015	TMC
November 2017	Document extended whilst under review	TLG
December 2017	Sentence added in at the request of the Coroner	
December 2017	Document extended for 3 months as per TLG recommendation	TLG
March 2018	Document extended for 3 months as approved by TLG	TLG
June 2018	Document extended for 3 months as approved by TLG	TLG
June 2019	Document extended for 6 months whilst review and approval process	Alison Hall

GUIDELINE FOR THE MANAGEMENT OF HYPEROSMOLAR NON-KETOTIC STATE (HONK)

GUIDELINE

Elderly patients may present with severe hyperglycaemia and dehydration in the absence of ketoacidosis. HONK is confirmed by severe hyperglycaemia (blood glucose in excess of 30mmol/l) and a calculated serum osmolality of 350mmol/l or greater (multiply sum of serum Na and K by 2, then add the concentrations of both urea and glucose). HONK is uncommon and may well be the first manifestation of diabetes mellitus.

Investigation and treatment for HONK is as for diabetic ketoacidosis (see Trust guideline) *except:*

Patients are often profoundly hypernatraemic. This can worsen with treatment. If the initial serum Na is 160mmol/l or greater, fluid replacement should commence with 0.45% saline. Serum electrolytes should be repeated after 2 hours of fluid resuscitation. If serum Na continues to rise, switch fluid replacement to 5% dextrose.

Patients with HONK are often very sensitive to insulin. Care should be taken to monitor blood glucose closely to avoid hypoglycaemia.

Patients with HONK often die from pulmonary embolism. All patients should receive full-dose heparin (Clexane 1.5mg/kg once daily) until fully mobile.

Bronchopneumonia is frequently present in patients with HONK. After blood cultures have been taken, commence a broad-spectrum antibiotic.

Patients with HONK are usually elderly and very sick. Mortality exceeds 10% in most series. Consider transfer to an HDU bed.

The recovery phase may be slow. Resolution of obtundation may lag some days behind biochemical recovery. Rehabilitation may require several weeks.

Insulin is not always needed in the long-term. The diabetes team should be involved at an early stage of the patient's management.

WAHT-END-008

This guideline has been printed from the Worcestershire Acute Hospitals NHS Trust intranet on
19/06/2019,13:02

It is the responsibility of every individual to check that this is the latest version/copy of this document.

MONITORING TOOL

STANDARDS	%	Clinical Exceptions
Commence fluid resuscitation within 30 minutes of assessment	95%	Major difficulty with venous access
Commence IV insulin within 30 minutes	95%	See above
Refer all patients to diabetes team	99%	Patient died within 6 hours

How will monitoring be carried out? Regular audit of admissions

When will monitoring be carried out? After 12 months

Who will monitor compliance with the guideline? Diabetes team

REFERENCES

Krentz, A. and Natrass, M. Acute Metabolic Complications of Diabetes: Diabetic ketoacidosis, hyperosmolar non-ketotic hyperglycaemia and lactic acidosis. In Chapter 32, Textbook of Diabetes, 3rd edition, eds J. Pickup, G. Williams. Blackwell Publishing. Oxford.

WAHT-END-008

This guideline has been printed from the Worcestershire Acute Hospitals NHS Trust intranet on
19/06/2019,13:02

It is the responsibility of every individual to check that this is the latest version/copy of this document.

CONTRIBUTION LIST**Key individuals involved in developing the document**

Name	Designation
Dr D Jenkins	Consultant Physician
Dr. P. Newrick	Consultant Physician
Dr. I. Babar	Consultant Physician

Circulated to the following individuals for comments

Name	Designation
Mrs. E. Innes	Diabetes Specialist Nurse
Mrs. L. Gilbert	Diabetes Specialist Nurse
Mrs. H. O’Gorman	Diabetes Specialist Nurse
Dr. W. Ellis	Consultant Physician
Dr. M. Marimon	Consultant Physician
Dr. J. Young	Specialist Registrar
Ms. R. Roadley-Battin	Pharmacist

Circulated to the following CD’s/Heads of dept for comments from their directorates / departments

Name	Directorate / Department
Dr. S. Digby	Clinical Director – Critical Care
Ms. R. Johnson	Consultant in Accident and Emergency
Mrs. S. Smith	Matron - MAU

Circulated to the chair of the following committee’s / groups for comments

Name	Committee / group
Mrs. A. Smith	Medicines Safety Committee